The market for therapeutics to treat Crohn’s disease is projected to grow at a CAGR of 7.6% from 2023 to 2029, reaching USD 23.63 billion by 2029, compared to USD 13.86 billion in 2022. Crohn’s disease, an inflammatory bowel disease, causes digestive tract inflammation and symptoms like abdominal pain, severe diarrhea, and weight loss. The market is dominated by Crohn’s disease in the inflammatory bowel disease treatment sector. The US has the highest prevalence of Crohn’s disease, followed by the UK and China. The rising prevalence drives the market’s growth. Over 100 assets are in development for Crohn’s disease, with most in Phase II. Anti-interleukin and integrin antibodies are the primary drugs in the pipeline. The US leads in global clinical trials. Biologics like anti-TNFs are widely used, but new therapies with better mechanisms of action and convenience are needed. Microbiome-based therapeutics show promise. Major companies invest in research, acquisitions, and collaborations. Multiple therapies have been launched, including Humira, Remicade, and Stelara. Five major companies have approved drugs for Crohn’s disease.
The report covers market size and growth, segmentation, competitive landscape, trends and strategies for global Crohn’s disease therapeutics market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.
The market is segmented based on various factors, including drug class, gender type, age group, disease type, and geography.
Drug class: 5-aminosalicylates, TNF-alpha inhibitors, others
Gender: men, women
Age group: 49 yrs. & below, 50 yrs. & above
Disease type: large intestinal type, small intestinal type, small/large intestinal type
Segmentation by Geography
North America – US
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan
TNF-Alpha inhibitors hold a significant share in the global Crohn’s disease therapeutics market, but other drug classes are expected to grow rapidly. Skyrizi’s approval will drive the market. New mechanisms of action are being researched to address non-response issues. Launch of new drugs for moderate-to-severe patients will contribute to market growth. Anti-integrin and interleukin inhibitors gain popularity. Women have a substantial presence. The small intestinal type grows fastest. Individuals aged 49 and below dominate. The US dominates, but the UK will grow rapidly. Biosimilars impact China and Japan.
The Crohn’s disease treatment market is dominated by generic medication providers and selective pharmaceutical and biotechnology companies. Key companies in this market include AbbVie Inc., AstraZeneca plc, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celltrion, Inc., Johnson & Johnson (J&J), Redhill Biopharma Ltd., Takeda Pharmaceutical Company Limited, UCB SA, among others.
AbbVie achieved a significant milestone in June 2022 with the FDA approval of SKYRIZI (risankizumab-rzaa), the first and only IL-23 inhibitor for moderately to severely active Crohn’s disease (CD). The approval was based on positive results from the ADVANCE and MOTIVATE studies, which evaluated risankizumab’s efficacy and safety in comparison to placebo.
In May 2022, AbbVie announced positive topline results from the Phase 3 U-ENDURE maintenance study, showing that upadacitinib demonstrated superior efficacy compared to placebo in achieving endoscopic response and clinical remission in patients with moderate to severe Crohn’s disease.
Ossium Health received FDA acceptance of its IND application for OSSM-001 in March 2022. OSSM-001, a mesenchymal stem cell product, aims to treat refractory perianal fistulas in Crohn’s disease patients. Ossium is now preparing for a Phase 1 clinical trial to evaluate the safety and efficacy of OSSM-001, expected to begin by the end of 2022.
To analyze and forecast the market size of the global Crohn’s disease therapeutics market.
To classify and forecast the global Crohn’s disease therapeutics market based on drug class, gender, age group, disease type, geography.
To identify drivers and challenges for the global Crohn’s disease therapeutics market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global Crohn’s disease therapeutics market.
To identify and analyze the profile of leading players operating in the global Crohn’s disease therapeutics market.
Gain a reliable outlook of the global Crohn’s disease therapeutics market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| Market Size (2022) | USD 13.86 Billion |
| Base Year | 2022 |
| Forecast Year | 2023-2029 |
| CAGR (2023-2029) | 7.62% |
| Pages | 88 |
| Segments By | Drug Class, Gender, Age Group, Disease Type, Geography |
| Regions Covered | Global |
| Key Players | AbbVie Inc., AstraZeneca plc, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celltrion Inc., Johnson & Johnson (J&J), Redhill Biopharma Ltd., Takeda Pharmaceutical Company Limited, UCB SA |
The global dental burs market is projected to expand at a CAGR of ~5.6 percent across the forecast period of 2024 – 2030, according to the latest edition of the…
The global urology laser market is estimated to increase at the rate of 5.6% each year in the period from 2023 to 2029. Urology lasers are medical devices specifically designed…
The global scar management market, in terms of revenue, is anticipated to progress at a CAGR of 5.8% during the forecast period, 2023-2029. Scar management encompasses various techniques and treatments…
Please fill out our form and we will get back to you.
